Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients

References

• de LauLMBretelerMMEpidemiology of Parkinson’s diseaseLancet Neurol20065652553510.1016/S1474-4422(06)70471-916713924
   PubMed Web of Science ®Google Scholar
• OertelWSchulzJBCurrent and experimental treatments of Parkinson disease: A guide for neuroscientistsJ Neurochem201613932533710.1111/jnc.1375027577098
   PubMed Web of Science ®Google Scholar
• FerreiraJJKatzenschlagerRBloemBRSummary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s diseaseEur J Neurol201320151510.1111/j.1468-1331.2012.03866.x23279439
   PubMed Web of Science ®Google Scholar
• SzászJConstantinVFazakasPThe role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson’s disease in the neurology clinics of Tirgu Mures county emergency clinical hospital [A szelektív monoaminoxidáz-B-gátlók helye a Parkinson-kór kezelési straté]Orv Hetil20171582023202810.1556/650.2017.3091429250969
   PubMed Web of Science ®Google Scholar
• HorstinkMTolosaEBonuccelliUReview of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European federation of neurological societies (EFNS) and the movement disorder society-European section (MDS-ES). Part II: late (complicated) Parkinson’s diseaseEur J Neurol200613111186120210.1111/j.1468-1331.2006.01548.x17038032
   PubMed Web of Science ®Google Scholar
• DezsiLVecseiLMonoamine Oxidase B Inhibitors in Parkinson’s diseaseCNS Neurol Disord Drug Targets201716442543910.2174/187152731666617012416522228124620
   PubMed Web of Science ®Google Scholar
• CiliaRAkpaluASarfoFSThe modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan AfricaBrain2014137102731274210.1093/brain/awu19525034897
   PubMed Web of Science ®Google Scholar
• SchapiraAHVMonoamine Oxidase B Inhibitors for the treatment of Parkinson’s diseaseCNS Drugs201125121061107110.2165/11596310-000000000-0000022133327
   PubMed Web of Science ®Google Scholar
• Aviles-OlmosIKefalopoulouZFoltynieTUnderstanding and prevention of “therapy-” induced dyskinesiasParkinsons Dis2012201264081510.1155/2012/64081522685687
   PubMed Web of Science ®Google Scholar
• SchapiraAHMcDermottMPBaronePPramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trialLancet Neurol201312874775510.1016/S1474-4422(13)70117-023726851
   PubMed Web of Science ®Google Scholar
• OlanowCWKieburtzKLeinonenMA randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson’s diseaseMov Disord201732578378910.1002/mds.2694128370340
   PubMed Web of Science ®Google Scholar
• ShillHAStacyMUpdate on ropinirole in the treatment of Parkinson’s diseaseNeuropsychiatr Dis Treat2009513336 http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L355664604%5Cnhttp://www.dovepress.com/getfile.php?fileID=409819557097
   PubMed Web of Science ®Google Scholar
• AntoniniAPoeweWChaudhuriKRLevodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registryParkinsonism Relat Disord201745132010.1016/j.parkreldis.2017.09.01829037498
   PubMed Web of Science ®Google Scholar
• BăjenaruOEneAPopescuBOThe effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experienceJ Neural Transm2016123440741410.1007/s00702-015-1496-z26699635
   PubMed Web of Science ®Google Scholar
• JuhászAAschermannZÁcsPLevodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson’s disease: an open-label studyParkinsonism Relat Disord201737798610.1016/j.parkreldis.2017.02.00128185758
   PubMed Web of Science ®Google Scholar
• SzászJConstantinVOrbán-KisKCharacteristics of dopaminergic treatments in advanced Parkinson’s before levodopa-carbidopa intestinal gel infusion: data from 107 tested patientsMov Disord201833171
   Web of Science ®Google Scholar
• SchapiraAHVOlanowCWDrug selection and timing of initiation of treatment in early Parkinson’s diseaseAnn Neurol200964S2S47S5510.1002/ana.21460
   Web of Science ®Google Scholar
• ScottLJOpicapone: A review in Parkinson’s diseaseDrugs201676131293130010.1007/s40265-016-0623-y27498199
   PubMed Web of Science ®Google Scholar
• BorgohainRSzaszJStanzionePRandomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuationsMov Disord201429222923710.1002/mds.2575124323641
   PubMed Web of Science ®Google Scholar
• BorgohainRSzaszJStanzionePTwo-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s diseaseMov Disord201429101273128010.1002/mds.2596125044402
   PubMed Web of Science ®Google Scholar
• BorgohainRSzaszJStanzionePFirst 2-year, controlled study to assess safinamide as add-on to levodopa in Parkinson’s disease with motor fluctuationsMov Disord2011262120121
   Google Scholar
• RosaMMFerreiraJJCoelhoMFreireRSampaioCPrescribing patterns of antiparkinsonian agents in EuropeMov Disord20102581053106010.1002/mds.2303820222132
   PubMed Web of Science ®Google Scholar
• MorrishPPrescribing in Parkinson’s disease: a story of hope and adverse eventsPract Neurol201212533534010.1136/practneurol-2012-00021022976066
   PubMedGoogle Scholar
• OsinagaEAInchaurreguiLCAIkobaltzetaIEAlonsoNBDel PozoJGA pharmacoepidemiological study of the consumption of antiparkinson drugs in the basque autonomous community (Spain) (1992–2004)Parkinsonism Relat Disord200713850050410.1016/j.parkreldis.2007.03.00417532251
   PubMed Web of Science ®Google Scholar
• PitcherTLMacAskillMRAndersonTJTrends in antiparkinsonian medication use in New Zealand: 1995–2011Parkinsons Dis2014201437943110.1155/2014/37943124729910
   PubMed Web of Science ®Google Scholar
• PeretzCSegevHRozaniVComparison of Selegiline and Rasagiline therapies in Parkinson Disease: a real-life studyClin Neuropharmacol201639522723110.1097/WNF.000000000000016727438181
   PubMed Web of Science ®Google Scholar
• LiJChenDSongWSurvey on general knowledge on Parkinson’s disease in patients with Parkinson’s disease and current clinical practice for Parkinson’s disease among general neurologists from Southwest ChinaClin Neurol Neurosurg2014118162010.1016/j.clineuro.2013.12.00924529223
   PubMed Web of Science ®Google Scholar
• YangJ-XChenLEconomic burden analysis of Parkinson’s disease patients in ChinaParkinsons Dis201720171710.1155/2017/8762939
   Web of Science ®Google Scholar
• SkogarONilssonMTörnhageC-JLökkJNational surveys: a way to manage treatment strategies in Parkinson’s disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on diseaseJ Multidiscip Healthc2013623924710.2147/JMDH.S4445123847426
   PubMedGoogle Scholar
• CrispoJAGFortinYThibaultDPTrends in inpatient anti-parkinson drug use in the USA, 2001–2012Eur J Clin Pharmacol20157181011101910.1007/s00228-015-1881-426081062
   PubMed Web of Science ®Google Scholar
• LiuWMWuRMChangCHLinJWLiuYCLinCHNational trends of Antiparkinsonism treatment in Taiwan: 2004–2011Parkinsons Dis20162016185932110.1155/2016/185932126989558
   PubMed Web of Science ®Google Scholar
• MöllerJCKörnerYDodelRCPharmacotherapy of Parkinson’s disease in GermanyJ Neurol2005252892693510.1007/s00415-005-0784-115765268
   PubMed Web of Science ®Google Scholar
• HaycoxAArmandCMurteiraSCochranJFrançoisCCost effectiveness of Rasagiline and Pramipexole as treatment strategies in early Parkinson’s disease in the UK settingDrugs Aging200926979180110.2165/11316770-000000000-0000019728752
   PubMed Web of Science ®Google Scholar
• KovacsNJanszkyJNagyFCost effectiveness of Rasagiline and Pramipexole as treatment Strategies in early Parkinson’s disease in the UK settingDrugs Aging201128216116210.2165/80-000000000-0000021275441
   PubMed Web of Science ®Google Scholar
• YunJYKimYEYangHJKimHJJeonBTwice-daily versus once-daily Pramipexole extended release dosage Regimens in Parkinson’s diseaseParkinsons Dis20172017851892910.1155/2017/851892928265478
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group CALM Cohort InvestigatorsLong-term effect of initiating Pramipexole vs Levodopa in early Parkinson diseaseArch Neurol200966556357010.1001/archneur.66.1.nct9000119433655
   PubMedGoogle Scholar
• AntoniniACalandrellaDOnce-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patientsNeuropsychiatr Dis Treat20117129730210.2147/NDT.S1009721654875
   PubMed Web of Science ®Google Scholar
• Di BiaseLBrittainJSShahSATremor stability index: A new tool for differential diagnosis in tremor syndromesBrain201714071977198610.1093/brain/awx10428459950
   PubMed Web of Science ®Google Scholar
• SzatmariSIlligensBM-WSiepmannTPinterATakatsABereczkiDNeuropsychiatric symptoms in untreated parkinson’s diseaseNeuropsychiatr Dis Treat20171381582610.2147/NDT.S13099728352181
   PubMed Web of Science ®Google Scholar
• HinsonVGainesKAdjunctive therapy in Parkinson’s disease: the role of rasagilineNeuropsychiatr Dis Treat201228529410.2147/NDT.S2514222802692
   PubMed Web of Science ®Google Scholar
• ZhangJTanLC-SRevisiting the medical management of Parkinson’s disease: levodopa versus Dopamine AgonistCurr Neuropharmacol2016144356363 http://www.ncbi.nlm.nih.gov/pubmed/26644151Accessed, 201826644151
   PubMed Web of Science ®Google Scholar
• SchröderSKuessnerDArnoldGZöllnerYJonesESchaeferMDo neurologists in Germany adhere to the national Parkinson’s disease guideline?Neuropsychiatr Dis Treat20117110311010.2147/NDT.S889521552312
   PubMed Web of Science ®Google Scholar
• LyonsKEPahwaROutcomes of Rotigotine clinical trialsNeurol Clin2013313S51S5910.1016/j.ncl.2013.04.01123931954
   PubMed Web of Science ®Google Scholar
• BaronePPoeweWAlbrechtSPramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trialLancet Neurol20109657358010.1016/S1474-4422(10)70106-X20452823
   PubMed Web of Science ®Google Scholar
• LeentjensAFGThe role of Dopamine Agonists in the treatment of depression in patients with Parkinson’s diseaseDrugs201171327328610.2165/11585380-000000000-0000021319866
   PubMed Web of Science ®Google Scholar
• TalatiRBakerWLPatelAAReinhartKColemanCIAdding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson’s disease: a meta analysisInt J Clin Pract200963461362310.1111/j.1742-1241.2009.02027.x19222614
   PubMed Web of Science ®Google Scholar
• PoeweWHRascolOQuinnNEfficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trialLancet Neurol20076651352010.1016/S1474-4422(07)70108-417509486
   PubMed Web of Science ®Google Scholar
• WattsRLLyonsKEPahwaROnset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s diseaseMov Disord201025785886610.1002/mds.2289020461803
   PubMed Web of Science ®Google Scholar